Pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for HIV-infected population

Background Tuberculosis is an important infection and is still the most important problem worldwide. The prevention of infection is an important consideration. Focusing on the risk group, HIV-infected patient group is an important risk population for getting tuberculosis. The use of pharmacoprophyla...

Full description

Bibliographic Details
Main Authors: Beuy Joob, Viroj Wiwanitkit
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Egyptian Journal of Chest Disease and Tuberculosis
Subjects:
hiv
Online Access:http://www.ejcdt.eg.net/article.asp?issn=0422-7638;year=2021;volume=70;issue=1;spage=78;epage=80;aulast=Joob
id doaj-53442710cffc44908c970e5fa975a3bc
record_format Article
spelling doaj-53442710cffc44908c970e5fa975a3bc2021-04-20T08:43:41ZengWolters Kluwer Medknow PublicationsEgyptian Journal of Chest Disease and Tuberculosis0422-76382090-99502021-01-01701788010.4103/ejcdt.ejcdt_217_19Pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for HIV-infected populationBeuy JoobViroj WiwanitkitBackground Tuberculosis is an important infection and is still the most important problem worldwide. The prevention of infection is an important consideration. Focusing on the risk group, HIV-infected patient group is an important risk population for getting tuberculosis. The use of pharmacoprophylaxis has become a new concept in preventive medicine against tuberculosis for HIV-infected population. The classical regimen is the isoniazid regimen. However, the new introduction of combined rifapentine and isoniazid has become a new alterative preventive measure that can help prevent tuberculosis among HIV-infected cases. The alternative is reported for its efficacy and also mentioned for the shorter period of drug use. Materials and methods In the present report, the authors performed a clinical mathematical modeling study to determine the pharmacoprophylactic equivalence of rifapentine compared with isoniazid, with special referencing to the HIV-infected population. First, the comparison of required dosage, period of treatment, as well as prophylactic end point is primarily performed and then appraisal on pharmacoprophylactic equivalence of rifapentine compared with isoniazid is done based on mathematical adjustment for required dosage, period of treatment, and prophylaxis end point. Results Based on the appraisal, the final pharmacoprophylaxis equivalence is 1 rifapentine dosage is equal to 4.002748–8.005496 isoniazid dosage or 1 mg rifapentine is equal to 0.00143 week of drug use. Conclusion Based on the derived pharmacoprophylactic equivalence, rifapentine can help lower required isoniazid dosage and period of prophylactic drug use in prevention of tuberculosis for HIV-infected case.http://www.ejcdt.eg.net/article.asp?issn=0422-7638;year=2021;volume=70;issue=1;spage=78;epage=80;aulast=Joobequivalencehivisoniazidprophylaxisrifapentinetuberculosis
collection DOAJ
language English
format Article
sources DOAJ
author Beuy Joob
Viroj Wiwanitkit
spellingShingle Beuy Joob
Viroj Wiwanitkit
Pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for HIV-infected population
Egyptian Journal of Chest Disease and Tuberculosis
equivalence
hiv
isoniazid
prophylaxis
rifapentine
tuberculosis
author_facet Beuy Joob
Viroj Wiwanitkit
author_sort Beuy Joob
title Pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for HIV-infected population
title_short Pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for HIV-infected population
title_full Pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for HIV-infected population
title_fullStr Pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for HIV-infected population
title_full_unstemmed Pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for HIV-infected population
title_sort pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for hiv-infected population
publisher Wolters Kluwer Medknow Publications
series Egyptian Journal of Chest Disease and Tuberculosis
issn 0422-7638
2090-9950
publishDate 2021-01-01
description Background Tuberculosis is an important infection and is still the most important problem worldwide. The prevention of infection is an important consideration. Focusing on the risk group, HIV-infected patient group is an important risk population for getting tuberculosis. The use of pharmacoprophylaxis has become a new concept in preventive medicine against tuberculosis for HIV-infected population. The classical regimen is the isoniazid regimen. However, the new introduction of combined rifapentine and isoniazid has become a new alterative preventive measure that can help prevent tuberculosis among HIV-infected cases. The alternative is reported for its efficacy and also mentioned for the shorter period of drug use. Materials and methods In the present report, the authors performed a clinical mathematical modeling study to determine the pharmacoprophylactic equivalence of rifapentine compared with isoniazid, with special referencing to the HIV-infected population. First, the comparison of required dosage, period of treatment, as well as prophylactic end point is primarily performed and then appraisal on pharmacoprophylactic equivalence of rifapentine compared with isoniazid is done based on mathematical adjustment for required dosage, period of treatment, and prophylaxis end point. Results Based on the appraisal, the final pharmacoprophylaxis equivalence is 1 rifapentine dosage is equal to 4.002748–8.005496 isoniazid dosage or 1 mg rifapentine is equal to 0.00143 week of drug use. Conclusion Based on the derived pharmacoprophylactic equivalence, rifapentine can help lower required isoniazid dosage and period of prophylactic drug use in prevention of tuberculosis for HIV-infected case.
topic equivalence
hiv
isoniazid
prophylaxis
rifapentine
tuberculosis
url http://www.ejcdt.eg.net/article.asp?issn=0422-7638;year=2021;volume=70;issue=1;spage=78;epage=80;aulast=Joob
work_keys_str_mv AT beuyjoob pharmacoprophylacticequivalenceofrifapentinecomparedwithisoniazidanappraisalforhivinfectedpopulation
AT virojwiwanitkit pharmacoprophylacticequivalenceofrifapentinecomparedwithisoniazidanappraisalforhivinfectedpopulation
_version_ 1721518166578823168